[Molecularly Targeted Therapy for Craniopharyngioma]

Area of Science:

• Neuro-oncology
• Molecular targeted therapy
• Genomic medicine

Background:

• Craniopharyngioma is a parasellar brain tumor, often benign pathologically but clinically malignant.
• Surgical resection is challenging due to vital structure adhesion, leading to frequent recurrence.
• Standard treatments like re-resection and radiotherapy carry significant risks such as blindness and hypopituitarism.

Purpose of the Study:

• To explore the efficacy of molecularly targeted therapy for papillary craniopharyngioma.
• To investigate the potential of BRAF and MEK inhibitors as an alternative treatment modality.

Main Methods:

• Review of genomic analysis identifying hotspot BRAF-V600E mutations in papillary craniopharyngioma.
• Analysis of case reports detailing responses to BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (trametinib).

Main Results:

• A significant proportion of papillary craniopharyngioma cases harbor the BRAF-V600E mutation.
• Case reports indicate dramatic responses to targeted therapy with BRAF and MEK inhibitors.
• These targeted agents are approved for other cancers like melanoma and non-small cell lung carcinoma.

Conclusions:

• Molecularly targeted therapy represents a promising treatment option for papillary craniopharyngioma.
• This approach may offer an alternative to surgery and radiotherapy, potentially mitigating severe treatment-related risks.
• Further investigation into targeted therapies for BRAF-V600E mutated craniopharyngioma is warranted.